Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Market Cap	$160.39M	P/E Ratio	NaN
52W High	$3.22	52W Low	$1.80
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	28.5%	52W Position	33.8%
Overall Score	58	Value Score	80
Quality Score	55	Technical Score	40

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SPRO	$2.28	+8.06%	7.20M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SPRO	$2.28	+8.1%	7.20M
3
4
5
6

SPRO

SPRO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Spero Therapeutics Inc. Data in Excel

Get Spero Therapeutics Inc. Data in Excel